Through the partnership, ACC will review Aidoc’s technology so it can better identify patients with CAC, a precursor to several cardiovascular diseases, even when they aren’t visiting a cardiologist, according to a Feb. 29 press release.
Aidoc’s FDA-cleared technology can communicate findings to radiologists to coordinate automatic patient follow-up care.
Even if a patient’s initial bodily scan is unrelated to cardiovascular concerns, Aidoc’s AI applies algorithms based on visible anatomy and reports any existing CAC risks to a radiology team.
The ACC and Aidoc partnership will focus on three things: refining solutions, integrating ACC guidelines and promoting health equity.
